Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 17/20 | 0.51 |
| ▸ | CCKAR | P32238 | 13/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29692185 | 1.00 | CCKBR (0.51) | CCKBRCCKAR | |
| SCHEMBL23023776 | 1.00 | CCKBR (0.51) | CCKBRCCKAR | |
| SCHEMBL29692187 | 0.90 | CCKBR (0.49) | CCKBRCCKAR | |
| SCHEMBL23013554 | 0.90 | CCKBR (0.49) | CCKBRCCKAR | |
| SCHEMBL29692277 | 0.90 | CCKBR (0.48) | CCKBRCCKAR | |
| SCHEMBL23013144 | 0.90 | CCKBR (0.48) | CCKBRCCKAR | |
| SCHEMBL28749205 | 0.89 | CCKBR (0.48) | CCKBRCCKAR | |
| SCHEMBL29692182 | 0.89 | CCKBR (0.48) | CCKBRCCKAR | |
| SCHEMBL29939348 | 0.88 | CCKBR (0.57) | CCKBRCCKAR | |
| SCHEMBL23013406 | 0.88 | CCKBR (0.48) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227507-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-02-18 | — | — | US | claimed |
| US-20220306639-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-09-29 | — | — | US | claimed |
| EP-4017856-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-06-29 | — | — | EP | claimed |
| WO-2021032992-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2021-02-25 | — | — | WO | claimed |
| US-12227507-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220324873-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-10-13 | — | — | US | disclosed |
| US-20220306639-A1 | PHARMACEUTICAL COMPOUNDS | PFIZER INC. | 2022-09-29 | — | — | US | disclosed |
| EP-4017856-A1 | PHARMACEUTICAL COMPOUNDS | Reviral Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| CN-114555604-A | Pharmaceutical compounds | 瑞威有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021032992-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032992-A1 | PHARMACEUTICAL COMPOUNDS | ReViral Limited (GB) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227507-B2 | Pharmaceutical compounds | CHRNA6, GABRA6, CHRNA7 | CCKBR 488/4885CCKAR 199/4885 |
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | CCKBR 257/4885CCKAR 168/4885 |
| US-20220306639-A1 | PHARMACEUTICAL COMPOUNDS | CHRNA6, GABRA6, CHRNA7 | CCKBR 488/4885CCKAR 199/4885 |
| US-20220324873-A1 | PHARMACEUTICAL COMPOUNDS | GABRA6, CNR1, CHRNA6 | CCKBR 408/4885CCKAR 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.